The performance of the domestic pharmaceutical bio industry is being evaluated with the approaching end of 2024.

This year, the increased influence of domestic companies in the fields of biosimilars and CDMOs (contract development and manufacturing) and the technology transfer performance of bio ventures have been positively evaluated. 

However, there is also a view that the investment in venture firms has slowed down due to the overall stringent investment market and that the government's plans to foster the bio-industry are still fragmented across ministries.

This is why the outlook for the domestic bio industry next year is also a mix of concerns and expectations.